Foghorn Therapeutics Inc.

Foghorn Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system. The company employs its proprietary Gene Traffic Control platform to identify and validate drug targets in this system, with the goal of creating therapies for patients with specific genetic cancer subtypes. Rather than pursuing broadly applicable cancer treatments, Foghorn targets mutations in genes such as androgen receptor in prostate cancer, as well as various other cancers including bladder, non-small cell lung, melanoma, endometrial, gastric, breast, colorectal, pancreatic, and hematologic malignancies.

The company's pipeline includes collaboration with Eli Lilly and Company on FHD-909, a selective BRM ATPase inhibitor. As a clinical-stage company, Foghorn currently derives no material revenue from product sales. The company operates primarily through research and development activities focused on advancing its drug candidates through clinical trials.

Foghorn maintains a lean operational structure with 112 full-time employees and is headquartered in Cambridge, Massachusetts. The company was incorporated in Delaware in 2015 and is listed on the Nasdaq exchange.